Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Cheers Benx4
As I said before Bioserv is just the UK arm of Calibre. This partnerships ability to sell significant quantities of tests across Europe has been massively overlooked by some, far too much focus on governments imo.
A thought that always go through my head……if Avacta just sell 2 million tests per month at say £1 profit each they are a profitable company. Now do you really think one of the worlds best tests doesn’t sell in at least those quantities.
So you have a early stage biotech which will be profitable with at least £35,000,000 sat on the balance sheet, I can’t think of any other biotechs at Avacta’s stage in such an envious position. The threat of dilution and funding that plagues so many early stage biotech companies is an afterthought.
What a fantastic position to be in and we still have AVA600 just 6 months away from 1st data. Not to mention the 5 partnerships that are ticking away in the background.
Never have I been more relaxed about a company and it’s prospects.
GLA.
IFU now in multiple languages
https://bioservuk.com/wp-content/uploads/2021/06/BioServUK-–-AffiDX-Lateral-Flow-Test-–-Multilanguage-IFU-ENDEFRESIT-V1.2.pdf
A few rumours that Medusa19 are planning to reverse into Location Sciences Group. Not hard to see why when you see their shareholders list and the concert party holdings:
https://www.locationsciencesgroup.ai/investor-relations/significant-shareholders/
One of the LS Group directors also has links to Deepverge and Microsaic who we know are both working with Avacta.
Below post on twitter is on the mark imo
https://twitter.com/tribal_state/status/1420051155187650560
Clearly the UK diagnostics industry is very angry right now
https://www.linkedin.com/posts/jonathanohalloran_innovation-quality-funding-activity-6824621394739896320-4qP9/
Q-POCs shipping is such a happy moment for me. We’ve been through hell and back, we’ve won funding, lost funding, been close to the edge over and over, we’ve been stonewalled, ignored and passed over in favour of our American competitors inferior device (shame on the government, the truth will come out) but still we survive and the quality of Q-POC shines through.
Avacta remain deadly silent though......
Yes it was but just to lack of resources prior to the fund raise Avacta prioritied the precision platform and rightly so imo.
The precision drugs are quicker to develop and are more likely to generate big licence deals faster. There are a large number of PD-L1 therapies on the market now so this programme was purely about getting human data. The commercial appetite for Precision pro drugs will be extremely high amongst large pharma imo. Also, the AVA600 data is critical to the TMAC program, which I think is the Jewell in the crown if Avacta’s vast pipeline.
Avacta are now using their strong balance sheet to develop bi-specific Affimer molecules, which potentially hold far more value. Again, all these programmes will also feed into the TMAC programmes.
Finally to be overlooked, it looks increasingly likely that LG Chem will take the PD-L1/XT Affimer into the clinic in the next 12 months, so no need for Avacta to progress it themselves.
https://digital2020.sensus.org/storage/581/Minerva_TRD.pdf
Seems some Imperial college students have been playing with Affimers. This time designing a biosensor to monitor epilepsy in patients.
Minerva is a team of ten undergraduate students, studying a variety of courses at Imperial College London. We are a motivated and ambitious team, with one common target shared; to design a biosensor for the detection of valproate in the blood and solve one of the main issues associated with the monitoring of epilepsy in patients. We have thrived on the unique experience SensUs have given us, to not only learn new skills and work with new people but also to follow an entire research and design process from start to finish!
Together, we have designed a microcantilever biosensor, utilising novel affimer technology to bind unbound valproate molecules (fVPA); allowing for label free detection. Our sensor features a unique microfluidic design, mixing modern pumping technology with a rarely seen droplet manipulation design. The use of SU-8 as the material of the microcantilever is rarely used commercially compared to the common use of silicon.
With the use of varied affimer technology and a replaceable cartridge our sensor also has the potential to be developed for detection of a variety of drugs and molecules, not only valproate!
Avacta’s Japanese distributor has them for sale also, along with more of the catalogue Affimers.
https://www.cosmobio.co.jp/product/detail/affimer-product-als.asp?entry_id=14177
Good to see Affimers getting commercial traction now, clearly the exposure of the last 12 months is helping massively in that regard:)
https://www.sigmaaldrich.com/GB/en/sds/mm/mabs1918
Safety sheet - print date 24/7/21
Just stumbled across this site selling Affimer reagents……
https://www.sigmaaldrich.com/GB/en/product/mm/mabs1918
Sigma Aldrich are part of Merck.
To be fair i did think the same but Avacta have chosen to update that page today all the same. Unless of course there is something else of relevance that needed updating.
Maybe I'm reading too much into it, but I always thought the 2.99% figure was interesting as it meant they were just at that point where they had to report it to Avacta........a coincidence or perhaps designed????
Investor key information page updated today - Conifer still at 2.99%
https://avacta.com/investors/key-information/
Thanks Ophidian that’s great info.
I think most of use suspected it was the frozen samples that was causing the issues as all the approved tests target the N protein. I’m guessing this issue is going to seriously impact Aptamer Group and Vatic also?
It does make you wonder why Mologic is having such an issue though as their targeting N protein, I’m guessing it’s the use of saliva.
Either way it’s a total shambles that the most one of the most sensitive LFT’s in the world which is of UK origin, can’t pass Porton Downs rigid process.
Question is can another route be found for Avacta??
The parent company getting in on the act now:)
https://www.linkedin.com/posts/calibrescientific_bioservuk-avacta-calibrescientific-activity-6823644594891321345-sopr/
Calibre Scientific, Inc. is proud to announce its partnership with Avacta Life Science for distributing their AffiDX® SARS-CoV-2 Lateral Flow Test which is developed and manufactured in the UK, based on their proprietary Affimer® technology.
Bioserv is only the UK arm of their vast distributor network remember.....
For the data nerds out there........and those struggling to get to sleep in the heat:)
Author is Rob Harrand - Head of Data, Systems and IT at Avacta.
https://towardsdatascience.com/affimer-proteins-next-generation-sequencing-data-analysis-part-1-ac6a252842be
https://towardsdatascience.com/affimer-proteins-next-generation-sequencing-data-analysis-part-2-8ebc0e90f460
https://towardsdatascience.com/affimer-proteins-next-generation-sequencing-data-analysis-part-3-90b4304413b5
https://www.linkedin.com/posts/bioservuk_bioservuk-avacta-calibrescientific-activity-6823617429671960576-eaS8/
BioServUK Ltd (A Calibre Scientific company - Calibre Scientific, Inc.) is proud to announce its partnership with Avacta Life Science for distributing their AffiDX® SARS-CoV-2 Lateral Flow Test which is developed and manufactured in the UK, based on their proprietary Affimer® technology.
Top Features of the Lateral Flow Test:
- 98% sensitivity and 99% specificity
- CE IVD marked
- MHRA registered
- Patient-friendly: Anterior nares (nasal) swabs samples for more comfortable collection
- Monitored against emerging Variants: Proven to detect the new Delta variant (B.1.617.2) as per a recent study
- Rapid & Simple: Easy to use, simple work-flow, results in only 20 minutes
We are ready to take orders!
Product code: BSV-COV-AVA62001
Product name: AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
Pack size: 1 Pack (25 Tests)
https://lnkd.in/g9YfCrk
info@BioServUK.com
+44 (0)114 224 2235
3 new recruits this month alone in the therapeutics division....
https://www.linkedin.com/in/rahul-sharma-77715719/
https://www.linkedin.com/in/rama-mccrorie-675bab80/
https://www.linkedin.com/in/tom-slocombe-792184105/
Some interesting experience on their CV's around covid projects as well. Maybe Mr Slocombe can have a word with his pals at Porton Down from his days working there, though it was 6 years ago:)
Good to see Avacta recruiting so heavily in both divisions
https://avacta.com/careers/careervacancies/
This is a vastly different business now from the one first invested in early last year:)
GLA
Thanks for posting Rebecca.
I’ve purchased through my business and got the same date also.
I think the Calibre deal has been far too overlooked. Just look at the list of countries there in and I’m not just talking Europe. Distributors are a key route to market, far too much focus on governments imho.
Revenue is flowing now and it will only go one way from here:)